Company profile: Cellerant Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage cell- and antibody-based immunotherapies.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellerant Therapeutics
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
Alethia Biotherapeutics
HQ: Canada
Website
- Description: Provider of monoclonal antibody-based therapeutics for cancer-associated diseases, including AB-16B5, a humanized IgG2 antibody targeting secreted clusterin to inhibit EMT, enhance chemotherapy response, and reduce tumor invasion; AB-3A4, developed as an ADC targeting KAAG1 for ovarian and triple-negative breast cancers; and STAR technology for discovering differentially expressed mRNA sequences, including rare ones, to identify novel therapeutic targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alethia Biotherapeutics company profile →
Kura Oncology
HQ: United States
Website
- Description: Provider of precision medicines for solid tumors and blood cancers, advancing investigational therapies including ziftomenib for AML with specific mutations, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other cancers, and KO-2806, a next-generation FTI for advanced solid tumors; also conducts clinical trials and offers expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kura Oncology company profile →
Dice Therapeutics
HQ: United States
Website
- Description: Provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral α4β7 for IBD, oral αVβ1/αVβ6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dice Therapeutics company profile →
Theraclone Sciences
HQ: United States
Website
- Description: Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclone Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellerant Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellerant Therapeutics
2.2 - Growth funds investing in similar companies to Cellerant Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellerant Therapeutics
4.2 - Public trading comparable groups for Cellerant Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →